Q-omics provides the consensus-scored TRIM3 profile across patient tissues and cancer cell-line models. TRIM3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TRIM3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TRIM3 protein abundance shows 38,595 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where TRIM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM3 survival associations across molecular data types. TRIM3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM3 RNA expression–survival associations across cancer types. High TRIM3 expression shows unfavorable associations in LUSC, MESO, ACC and BLCA, but favorable associations in UCEC and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for TRIM3 RNA expression.
This table summarizes TRIM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM3 shows lower tumor expression in THCA, LUAD and KICH and higher tumor expression in KIRC, LIHC and HNSC. The KIRC box plot shows higher TRIM3 RNA expression in tumor versus normal tissue (log2 FC = +0.518, t-test p < 0.001).
This table shows molecular features associated with TRIM3 in patient tissues and cancer cell lines. In patient samples, TRIM3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
